Where does Detlev Biniszkiewicz work?

Detlev Biniszkiewicz is Managing Director at MPM BioImpact and Board director at iTeos Therapeutics and Board director at Rekindle Therapeutics and Board director at NextPoint Therapeutics.

What boards does Detlev Biniszkiewicz sit on?

Detlev Biniszkiewicz holds tracked board seats at NextPoint Therapeutics.

Where did Detlev Biniszkiewicz go to school?

Detlev Biniszkiewicz studied at Massachusetts Institute of Technology (Ph.D. and Post-Doc Research, Genetics).

Detlev Biniszkiewicz

Investor

Managing Director at MPM BioImpact · Board director at iTeos Therapeutics · Board director at Rekindle Therapeutics · Board director at NextPoint Therapeutics

Boston, Massachusetts

About

Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.

Board director at iTeos Therapeutics

Intro paths

→

In turn, Detlev can intro founders to iTeos Therapeutics's investors below.

iTeos Therapeutics's investors · 2

MPM BioImpactBoston · $1M – $15M checks · since 2020 VIVES PartnersWavre · $108K – $7.6M checks · since 2020

Co-founders at iTeos Therapeutics

Michel DetheuxExecutive Officer, Director

Board director at Rekindle Therapeutics

Intro paths

→

In turn, Detlev can intro founders to Rekindle Therapeutics's investors below.

Rekindle Therapeutics's investors · 1

MPM BioImpactBoston · $1M – $15M checks · since 2018

Board director at NextPoint Therapeutics

Intro paths

→

In turn, Detlev can intro founders to NextPoint Therapeutics's investors below.

NextPoint Therapeutics's investors · 7

Catalio Capital ManagementNew York · since 2024 Catalio Capital Management, LPNew York InvusNew York · since 2024 Leaps by BayerLeverkusen · since 2024 MPM BioImpactBoston · $1M – $15M checks · since 2024 Sanofi VenturesCambridge · $5M checks · since 2024 Sixty Degree CapitalNorth York · since 2024

Co-founders at NextPoint Therapeutics

Gordon FreemanScientific Founder

XingXing ZangScientific Founder

Experience

MPM BioImpactManaging Director/Investment Partner - MPM Innovation Fundcurrent2020 — present
MPM BioImpactFounder, Chairman, & Former CEO - NextPoint Therapeutics2018 — 2024
MPM BioImpactFounder, President & CEO - Sieben Therapeutics2020 — 2023
MPM BioImpactExecutive Partner & Serial Entrepreneur2018 — 2022
NextPoint Therapeutics, Inc.Founder, Chairman of the Boardcurrent2022 — presentGreater Boston
NextPoint Therapeutics, Inc.Founder, CEO, and President2018 — 2023Greater Boston
Montis BiosciencesBoard of Directors - Independent2019 — 2024
iTeos TherapeuticsBoard of Directors2019 — 2023Greater Boston
1K OncologyFounder/CEO2020 — 2022Greater Boston
Maverick TherapeuticsBoard of Directors2018 — 2021San Francisco Bay Area
Tilos TherapeuticsBoard of Directors - Independent2018 — 2020Greater Boston Area
Surface Oncology Inc.Board Of Directors2015 — 2018
Surface Oncology Inc.President & CEO2015 — 2017Greater Boston Area
AstraZenecaVice President, Oncology - Strategy, External Science & Licensing2011 — 2015Greater Boston Area
NovartisGlobal Head - Portfolio Management & Analysis2008 — 2011Greater Boston Area
NovartisHead - Strategic Projects and Planning2007 — 2008Greater Boston Area
Boston Consulting GroupPrincipal2001 — 2007Greater Boston Area

Skills & more

Biotechnology41Drug Discovery34Lifesciences12Oncology31Biopharmaceuticals12Technology Transfer6Clinical Development12Drug Development13Business Strategy1Clinical Research1Commercialization4Cross-functional Team Leadership3

+11 more

Clinical TrialsCancerCell BiologyBiomarkersGeneticsGenomicsImmunologyLife SciencesStrategyPharmaceutical IndustryLeadership

From Detlev's professional profile.

Investments

Board seats

NextPoint Therapeutics

Per SEC Form D filings.

Colleagues at MPM BioImpact

Alim Ladha

Senior Associate at MPM Capital

Andrew Scharenberg

Entrepreneur Partner at MPM BioImpact

Ansbert Gadicke, M.D.

Chairman at MPM BioImpact

Ansbert K. Gadicke

Managing Partner at MPM BioImpact

Aparna Parikh

Entrepreneur Partner at MPM BioImpact

Bard Geesaman

Managing Partner at MPM Capital

Binsen Li

Principal at MPM BioImpact

Brendan Furey

Chief Compliance Officer at MPM BioImpact

Network5

Alim Ladha

Senior Associate at MPM Capital

Ansbert K. Gadicke

Managing Partner at MPM BioImpact

Bard Geesaman

Managing Partner at MPM Capital

Briggs Morrison

Entrepreneur Partner at MPM BioImpact

Dan Hicklin

Managing Partner at MPM Capital

Investors connected to Detlev in public investor directories — a warm-intro map.

Frequently asked questions

Who is Detlev Biniszkiewicz?: Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.
Where does Detlev Biniszkiewicz work?: Detlev Biniszkiewicz is Managing Director at MPM BioImpact and Board director at iTeos Therapeutics and Board director at Rekindle Therapeutics and Board director at NextPoint Therapeutics.
What boards does Detlev Biniszkiewicz sit on?: Detlev Biniszkiewicz holds tracked board seats at NextPoint Therapeutics.
Where did Detlev Biniszkiewicz go to school?: Detlev Biniszkiewicz studied at Massachusetts Institute of Technology (Ph.D. and Post-Doc Research, Genetics).